Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT
- Wednesday, May 4, 2022, 2:26
- Business
- Add a comment
PARIS, May 4, 2022 /PRNewswire/ — Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announced that research on its AAV-Ligand Conjugates platform (ALIGATER) will…
About the Author
adminasapcorp has written 41538 stories on this site.